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Abstract
Aims/hypothesis The central nervous system (CNS) is a major
player in the regulation of food intake. The gut hormone
glucagon-like peptide-1 (GLP-1) has been proposed to have
an important role in this regulation by relaying information
about nutritional status to the CNS. We hypothesised that
endogenous GLP-1 has effects on CNS reward and satiety
circuits.
Methods This was a randomised, crossover, placebo-
controlled intervention study, performed in a university med-
ical centre in the Netherlands. We included patients with type
2 diabetes and healthy lean control subjects. Individuals were
eligible if they were 40–65 years. Inclusion criteria for the
healthy lean individuals included a BMI <25 kg/m2 and
normoglycaemia. Inclusion criteria for the patients with type
2 diabetes included BMI >26 kg/m2, HbA1c levels between 42
and 69 mmol/mol (6.0–8.5%) and treatment for diabetes with
only oral glucose-lowering agents. We assessed CNS activa-
tion, defined as blood oxygen level dependent (BOLD) signal,
in response to food pictures in obese patients with type 2
diabetes (n=20) and healthy lean individuals (n=20) using
functional magnetic resonance imaging (fMRI). fMRI was
performed in the fasted state and after meal intake on two
occasions, once during infusion of the GLP-1 receptor antag-
onist exendin 9-39, which was administered to block actions
of endogenous GLP-1, and on the other occasion during saline
(placebo) infusion. Participants were blinded for the type of
infusion. The order of infusion was determined by block
randomisation. The primary outcome was the difference in
BOLD signal, i.e. in CNS activation, in predefined regions
in the CNS in response to viewing food pictures.
Results All patients were included in the analyses. Patients
with type 2 diabetes showed increased CNS activation in
CNS areas involved in the regulation of feeding (insula,
amygdala and orbitofrontal cortex) in response to food pic-
tures compared with lean individuals (p≤0.04). Meal intake
reduced activation in the insula in response to food pictures in
both groups (p≤0.05), but this was more pronounced in
patients with type 2 diabetes. Blocking actions of endogenous
GLP-1 significantly prevented meal-induced reductions in
bilateral insula activation in response to food pictures in
patients with type 2 diabetes (p≤0.03).
Conclusions/interpretation Our findings support the hypothe-
sis that endogenous GLP-1 is involved in postprandial satiating
effects in the CNS of obese patients with type 2 diabetes.
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Introduction
The role of the central nervous system (CNS) in the regulation
of energy balance involves a complex interaction of signals
originating from the periphery (i.e. hormones and neuronal
signals) and responses of brain areas involved in the reward
and regulation of food intake [1]. An excess of food intake
compared with energy expenditure induces a chronically pos-
itive energy balance causing weight gain and obesity. In the
search for strategies to treat and prevent obesity, it is important
to increase understanding of the central regulation of feeding
and the physiological signals influencing this regulation.
Hormones derived from the gut appear to relay meal-
related information on nutritional status to the CNS, there-
by affecting feeding [2]. The gut hormone glucagon-like
peptide-1 (GLP-1) is released by enteroendocrine L cells
into the circulation following food ingestion. GLP-1 is
known for its incretin effect, as it augments meal-related insu-
lin secretion from the pancreas [3]. In addition, results from
preclinical and clinical studies demonstrate that administration
of GLP-1 or GLP-1 receptor agonists (GLP-1RA) in pharma-
cological amounts reduces appetite, food intake and body
weight [4–8]. In animal studies, the pharmacological effects
of GLP-1RA are at least partly mediated through the CNS
[9–15]. Results from studies in rodents and humans demon-
strate that endogenous GLP-1 (i.e. at lower levels of GLP-1
compared with pharmacological administration of GLP-1RA)
plays a role in the regulation of food intake [16, 17]. Although
studies in rodents indicate that this effect is also mediated via
the CNS [11, 18], the involvement of endogenous GLP-1 in
the central regulation of food intake in humans has not been
investigated.
Neuroimaging techniques enable non-invasive investiga-
tion of the CNS in humans. Functional magnetic resonance
imaging (fMRI) can be used to measure food-cue related
changes in activity in the CNS. Obese individuals show
increased activation when viewing food pictures [19] and
in particular pictures of high-energy food [20, 21]. In addi-
tion, it was shown that food intake reduces CNS activation
in response to viewing food pictures [22]. Furthermore, we
recently demonstrated that acute administration of pharma-
cological amounts of a GLP-1RA diminishes activation to
food pictures in areas involved in the regulation of food
intake [19].
In the present study, we used fMRI to assess the physiolog-
ical role of GLP-1 in the central regulation of food intake in
obese patients with type 2 diabetes and healthy lean individ-
uals. We measured CNS activation in response to viewing
food pictures before and after intake of a meal on two test
visits. During one of the visits, the GLP-1 receptor antagonist
exendin 9-39 was administered to evaluate the effects of
endogenous GLP-1. We hypothesised that the satiating effects
of meal intake on CNS activation would be prevented by
blocking endogenous GLP-1.
Methods
Participants The study was approved by the Medical Ethics
Review Committee of the VU University Medical Center
(VUMC) and conducted in accordance with the
Declaration of Helsinki. All participants provided written
informed consent. The study included 20 overweight and
obese patients with type 2 diabetes and 20 healthy lean
individuals matched for sex and age. Individuals were eligi-
ble if they were 40–65 years of age and right-handed.
Inclusion criteria for the healthy lean individuals included
a BMI <25 kg/m2 and normoglycaemia, defined by fasting
plasma glucose <5.6 mmol/l and 2 h glucose <7.8 mmol/l
following a 75 g oral glucose tolerance test. Inclusion
criteria for the patients with type 2 diabetes included BMI
>26 kg/m2, HbA1c levels between 42 and 69 mmol/mol
(6.0–8.5%) and treatment for diabetes of the oral glucose-
lowering agents metformin ± sulfonylurea. Exclusion criteria
were a history of neurological, cardiovascular, renal or liver
disease, malignancies, the use of any centrally acting agent,
substance abuse and psychiatric disorders. All patients with
diabetes were treated with metformin and 12 patients were
also treated with sulfonylurea, but sulfonylurea were tempo-
rarily discontinued 4 weeks prior to the start of the experi-
ments. Ten patients used antihypertensive medication and 15
patients used cholesterol-lowering agents.
General experimental protocol This was a placebo-
controlled, crossover, acute intervention study. The study
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consisted of two separate test visits. On each visit, two fMRI
scans were performed; one while the individual fasted and one
at 30 min after intake of a standardised liquid meal consisting
of 1,883 kJ (carbohydrate 56.1 g, fat 17.4 g and protein 18.0 g,
300 ml Nutridrink yoghurt style, Nutricia, Zoetermeer, the
Netherlands). At each visit, a catheter was inserted into a
cubital vein for infusion of, in random order, either placebo
(sodium chloride 0.9% wt/vol.) or the selective GLP-1 recep-
tor antagonist exendin 9-39 (600 pmol kg−1 min−1; Clinalfa,
Bachem, Bubendorf, Switzerland, used to block the effects
of endogenous GLP-1), using a MRI-compatible infusion
pump (MRIdium 3850 MRI-IV pump, Iradimed, Winter
Park, FL, USA). The order of infusion was determined by
block randomisation. Each infusion was started 1 h before
the beginning of the MRI scan and was continued during the
whole period of scanning. The participants were blinded for
the type of infusion. Blood was drawn at fixed intervals to
measure glucose, GLP-1, insulin and glucagon levels
(Fig. 1a).
fMRI paradigm The fMRI task has been described previously
[19]. Briefly, the fMRI task consisted of pictures selected
from three different categories: (1) high-energy food items;
(2) low-energy food items; (3) non-food items. The pictures
were presented via the software E-prime 1.2 (Psychology
Software Tools, Pittsburgh, PA, USA). Forty-two pictures
per category were presented in a block design (Fig. 1b).
The order of the blocks was randomised. Given that each
participant was scanned four times, four versions of this par-
adigm were created with different pictures, with the images
being matched between the versions and between the catego-
ries for type, shape and colour.
MRI acquisition and analyses Comparable MRI acquisi-
tion and analyses were used as described previously [19].
In brief, MRI data were acquired on a 3.0 Tesla GE Signa
HDxt scanner (General Electric, Milwaukee, WI, USA)
and fMRI data were acquired using an echo planar imag-
ing T2* blood oxygen level dependent (BOLD) pulse-se-
quence. Functional images were analysed with SPM8 soft-
ware (Wellcome Trust Centre for Neuroimaging, London,
UK). At the first level, high-energy food, low-energy food
and non-food blocks were modelled. Next, we computed
two contrasts of interest: all food pictures > non-food pictures;
high-energy food pictures > non-food pictures. These first-
level contrast images were entered into second-level three-
way ANOVA with factors group (healthy lean, diabetes), in-
fusion (placebo, exendin 9-39) and meal state (fasted, post-
prandial). A priori regions of interest (ROIs) were determined
based on previous studies (i.e. left and right insula, caudate
nucleus, putamen, amygdala and orbitofrontal cortex (OFC))
[19–21]. CNS activations are reported as significant when
they survive family-wise error correction for multiple compar-
isons on the voxel level using small volume correction within
predefined ROIs, as described previously [19].
Blood sampling and assays Measurement of blood glucose
was performed using the glucose dehydrogenase method
(GlucoseAnalyser, HemoCue, Ängelholm, Sweden). Total
GLP-1 was analysed using a C-terminally directed radioimmu-
noassay for amidated GLP-1 (antibody 89390) [23]. Insulin
levels were measured using an immunometric assay (Advia
Centaur, Siemens Medical Solutions Diagnostics, Tarrytown,
NY, USA). Glucagon levels were determined using an immu-
noassay as described previously (Lilly Research Laboratories,
Indianapolis, IN, USA) [24].
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Fig. 1 Study protocol. (a) Study design. Obese patients with type 2
diabetes and healthy lean individuals were studied in a placebo-controlled
acute intervention study. The study consisted of two visits (random
order): one with a GLP-1 receptor antagonist (exendin 9-39) infusion
and one with a saline (placebo) infusion. Infusions started 1 h before
the scan and lasted until the end of the visit. During each visit, two fMRI
scans were performed: one while fasted and one 30 min after the meal
intake. During fMRI, visual-food cues were presented. Blood samples
and appetite-related scores on a 10-point Likert scale were taken at fixed
time points. T1, structural MRI, T1-weighted sequence. (b) fMRI para-
digm. One run comprised six blocks of 21 s each (seven pictures). Within
one run, two blocks of each category were presented. Each MRI session
included three runs
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Questionnaires The participants were asked to score their
sensations of hunger, fullness, prospective food consumption
and nausea on a 10-point Likert scale at four fixed time points
during the visits: (1) before the start of the first (fasted) MRI
session; (2) before intake of the meal; (3) 30 min after meal
intake; (4) 60 min after meal intake. Changes in scores from
before meal intake to 30 and 60min after intake were analysed
and compared between infusions.
Statistical analyses Clinical group data were analysed with
the Statistical Package for the Social Sciences version 20
(IBM SPSS Statistics for Windows, Version 20.0. Armonk,
NY, USA). Data are expressed as mean ± SEM (unless other-
wise stated). Between-group differences were analysed with
independent Student’s t test. In cases of measurements with
more than one time point on each visit, repeated measures
ANOVAwas used with time (min) as the within-subject factor
and group as the between-subject factor, or treatment as the
within-subject factor. Results were considered statistically sig-
nificant when p<0.05.
Results
Baseline characteristics Table 1 summarises the baseline
characteristics of both groups. All participants completed all
visits. Due to a technical failure, one postprandial scan of a
patient with diabetes during the visit with exendin 9-39 infu-
sion could not be used in the analysis.
The effects of group, meal intake and GLP-1 receptor
blockade on CNS activation are presented in Table 2.
Increased CNS activation in response to viewing food
pictures in obese patients with type 2 diabetes vs healthy
lean individuals During the session with placebo infusion in
the fasted condition, obese patients with type 2 diabetes
showed increased activation in the right OFC (p=0.004), left
amygdala (p=0.02) and bilateral insula (right p=0.02 and left
p=0.04, respectively) in response to food pictures (Fig. 2) and
in the right OFC (p=0.05) and left insula (p=0.04) in response
to high-energy food pictures. However, in the postprandial con-
dition, increased activation in patients with diabetes was no
longer observed in any brain area studied. In addition, we did
not observe increased activation in healthy lean individuals
compared with patients with diabetes in any of the ROIs either
in the fasted or in the postprandial condition.
Meal intake reduced CNS activation in response to food
pictures During placebo infusion, both groups showed
reduced CNS activation in response to food pictures in the
postprandial condition compared with the fasted condition.
In healthy lean individuals, this effect of meal intake was
observed in the right insula in response to food pictures
(p=0.02; Fig. 3a). In addition, meal intake tended to reduce
activation in the right insula in response to the high-energy
food pictures in lean healthy individuals (p=0.08). In obese
patients with type 2 diabetes, CNS activation was also
reduced after meal intake in the bilateral insula in response
to viewing food pictures (right p=0.04, left p=0.05; Fig. 3b)
Table 1 Baseline characteristics
Characteristic Healthy controls (n=20) Obese T2DM patients (n=20) p value
Age (years) 56.3±1.4 59.5±0.9 0.06
Sex, male/female (n) 10/10 11/9 0.8
Weight (kg) 69.9±2.5 95.4±3.4 <0.001
BMI (kg/m2) 22.5±0.4 32.0±1.1 <0.001
Waist circumference (cm) 81.4±1.8 108.9±2.5 <0.001
Body fat (%) 24.7±1.3 38.6±1.8 <0.001
Systolic BP (mmHg) 113±3.5 128±2.0 0.001
Diastolic BP (mmHg) 72.9±2.5 78±1.8 0.1
HbA1c (mmol/mol) 37±0.4 56±2.2 <0.001
HbA1c (%) 5.5±0.03 7.3±0.2 <0.001
Fasting plasma glucose (mmol/l) 5.2±0.1 8.4±0.3 <0.001
Total cholesterol (mmol/l) 5.2±0.2 4.5±0.3 0.07
Triacylglycerol (mmol/l) 0.8±0.1 1.6±0.1 <0.001
Diabetes duration (years) – 7.8±1.1 –
BP-lowering medications (n) 0 10 <0.001
Cholesterol-lowering medications (n) 0 15 <0.001
Data are means ± SEM or number of individuals (n)
T2DM, type 2 diabetes
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and in the left insula (p=0.04), left caudate nucleus
(p=0.007) and right OFC (p=0.06) in response to viewing
high-energy food pictures. The effect of meal intake was
more pronounced in patients with diabetes compared with
healthy lean individuals in the right insula (p=0.008) and
bilateral OFC (right p=0.01, left p=0.03) in response to
food pictures.
Blockade of the GLP-1 receptor prevents effects of meal
intake on CNS activation in response to food pictures In
healthy lean individuals, the effect of GLP-1 receptor block-
ade tended to be statistically significant in the right insula
(p=0.08), indicating that the reducing effect of meal intake
on CNS activation in response to viewing food pictures may
have been blunted by GLP-1 receptor blockade. In obese
patients with type 2 diabetes, however, the reducing effect of
meal intake on CNS activation was largely prevented in the
bilateral insula by GLP-1 receptor blockade in response to
viewing food pictures (right p=0.04, left p=0.03). In addition,
the reducing effect of meal intake on CNS activation was
prevented by the GLP-1 receptor blockade in the right OFC
(p=0.04) and tended to be prevented in the left caudate nucle-
us (p=0.06) and left insula (p=0.08) in response to viewing
high-energy food pictures (Fig. 4).
Table 2 Effects of group, meal intake and GLP-1 receptor blockade on CNS activation in response to viewing of food pictures and high-energy food
pictures
Contrast used Comparison Region Side Cluster Z FWE p value MNI coordinates
(x, y, z)
Group differences
Food > non-food Healthy controls > T2DM (fasted, placebo) – – – – – –
High-energy > non-food – – – – – –
Food > non-food T2DM > Healthy controls (fasted, placebo) Amygdala L 13 2.79 0.02 −27, −4, −17
Insula R 41 3.24 0.02 29, 2, −14
Insula L 13 2.99 0.04 −30, 14, −17
OFC R 61 3.77 0.004 39, 26, −11
High-energy > non-food Insula L 19 3.21 0.02 −30, 14, −14
OFC R 16 2.87 0.05 42, 29, −11
Food > non-food Healthy controls > T2DM (postprandial, placebo) – – – – – –
High-energy > non-food – – – – – –
Food > non-food T2DM > Healthy controls (postprandial, placebo) – – – – – –
High-energy > non-food – – – – – –
Meal effects
Food > non-food Healthy controls: fasted > postprandial (placebo) Insula R 9 3.16 0.02 36, −16, 7
High-energy > non-food Insula R 6 2.67 0.08 36, −16, 7
Food > non-food T2DM: fasted > postprandial (placebo) Insula R 11 3.00 0.04 39, 2, −14
Insula L 24 2.85 0.05 −42, 11, −8
High-energy > non-food Caudate nucl. L 38 3.58 0.007 −12, 23, 1
Insula L 23 2.96 0.04 −36, 8, −14
OFC R 14 2.84 0.06 45, 29, −14
Effects of GLP-1 receptor blockade on meal effects
Food > non-food Healthy controls: meal reducing effects placebo > ex9-39 Insula R 33 2.70 0.08 36, −13, 7
High-energy > non-food – – – – – –
Food > non-food T2DM: meal reducing effects placebo > ex9-39 Insula R 38 3.18 0.02 48, 8, 4
Insula L 22 3.10 0.03 −27, 26, 1
High-energy > non-food OFC R 11 3.00 0.04 48, 29, −11
Caudate nucl. L 15 2.79 0.06 −12, 23, 1
Insula L 16 2.69 0.08 −27, 26, 1
This table describes the areas where significant differences in CNS activations were observed for the three comparisons (group differences, effects of
meal intake and effects of blockade of the GLP-1 receptor in both groups). For each comparison, the two contrasts (activation during food > non-food
pictures and high-energy food > non-food pictures) are presented. The areas with significant differences are listed, including the cluster size of this effect,
the Z value and the FWE corrected p value after small volume correction. The last column describes the coordinates of the peak voxel of the observed
difference in MNI space
Caudate nucl. caudate nucleus; ex9-39, exendin 9-39; FWE, family-wise error; L, left; MNI,Montreal Neurological Institute; R, right; T2DM, obese type
2 diabetes patients
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Fig. 2 Between-group
differences on CNS activation in
response to viewing food
pictures. (a) Axial and (b) coronal
slices showing average
differences in activation in brain
regions where patients with
diabetes vs healthy lean
individuals had hyperactivation in
response to viewing food
pictures. The colour scale reflects
the T-value of functional activity.
Results are presented at the
threshold of p<0.05, FWE
corrected on cluster extent. In the
graphs, the BOLD signal intensity
(effect size [AU]) for each group
is plotted as mean and SEM for
(c) the right and (d) left insula,
(e) right OFC and (f) left
amygdala. AU, arbitrary units;
FWE, family-wise error; HC,
healthy lean controls/individuals;
T2DM, type 2 diabetes patients
Fig. 3 Meal intake effects on CNS activation in response to viewing food
pictures. Coronal slices showing areas where intake of the meal reduced
activation in response to viewing food pictures 30 min after intake in (a)
healthy lean individuals and (b) obese patients with diabetes. The colour
scale reflects the T-value of functional activity. Results are presented at
the threshold of p<0.05, FWE corrected on cluster extent. In the graphs,
the BOLD signal intensity (effect size [AU]) mean and SEM is plotted for
healthy lean individuals in (c) the right insula and for patients with
diabetes in (d) the right and (e) left insula. AU, arbitrary units; FWE,
family-wise error; HC, healthy lean controls/individuals; T2DM, type 2
diabetes patients
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Appetite-related scores In the healthy lean group, no signif-
icant differences in postprandial changes in any of the
appetite-related scores were observed between the two exper-
imental days (data not shown). However, in the patients with
diabetes, exendin 9-39 infusion prevented the postprandial
reductions in the scores for hunger that were observed with
placebo 60 min after meal intake (mean ± SEM −2.3±0.7
during placebo vs −1.1±0.4 during exendin 9-39; p=0.02).
This effect was not significant at 30 min after meal intake
(p=0.5). Postprandial changes in the other scores did not
differ significantly between the infusions.
Blood glucose and plasma hormone levels Figure 5 shows
the glucose and hormone responses during both test visits.
Glucose levels were significantly higher in patients with type
2 diabetes compared with healthy lean individuals during both
placebo and exendin 9-39 administration (p<0.001 for both).
Compared with placebo, exendin 9-39 had no effect on glucose
levels in healthy lean individuals (p=0.4), whereas in patients
with diabetes, glucose levels were significantly higher through-
out the test visit with exendin 9-39 compared with placebo
(p<0.001). There were no significant differences in GLP-1
levels between healthy lean individuals and patients with dia-
betes during placebo infusion (p=0.2), but in both groups,
GLP-1 levels were significantly higher during exendin 9-39
infusion (p=0.04 and p=0.002 vs placebo in healthy lean indi-
viduals and patients with diabetes, respectively). Insulin levels
did not differ between groups during placebo infusion (p=0.3),
and were unaffected by exendin 9-39 (p=0.09 and p=0.4
vs placebo in healthy lean individuals and patients with diabe-
tes, respectively). During placebo infusion, glucagon levels
were significantly higher in patients with diabetes compared
with healthy lean individuals (p=0.004), with levels being
increased by exendin 9-39 compared with placebo (p=0.004
and p<0.001, respectively).
Adverse events Four individuals experienced abdominal dis-
comfort 1–2 h after intake of the liquid meal (n=2 during both
visits, n=1 during placebo and n=1 during exendin 9-39
administration). One individual vomited shortly after the
intake of the liquid meal on the visit with exendin 9-39. One
individual experienced dizziness after the first fMRI session
with exendin 9-39 for approximately 10 min.
Discussion
Using fMRI we observed that while viewing food pictures,
obese patients with type 2 diabetes display hyperactivation in
CNS areas involved in the regulation of food intake.
Furthermore, meal intake reduced CNS activation in healthy
lean individuals and in obese patients with type 2 diabetes, but
this effect was more pronounced in patients with diabetes. We
found that in patients with diabetes, the GLP-1 receptor
antagonist exendin 9-39 significantly prevented the reducing
effect of meal intake on CNS activation. This finding provides
the first evidence in humans for an effect of endogenous
GLP-1 on CNS activation in areas involved in the regulation
of feeding, supporting the concept that GLP-1 has a physio-
logical role in the central regulation of feeding.
Animal and human studies have demonstrated that admin-
istration of pharmacological amounts of GLP-1RA results in
reduced appetite, food intake [4–7] and body weight [8], and
these effects are at least partly mediated by effects on the CNS
[9–14, 19]. However, the physiological role of GLP-1 in the
central regulation of feeding is less clearly established.
Although not found consistently [25], treatment with the
selective GLP-1 RA exendin 9-39 [17, 18, 26, 27] has resulted
in significant increases in food intake [16]. In addition, in rats,
central endogenous GLP-1 affects food intake and body
weight [11, 18]. In humans, the effects of endogenous GLP-
1 on prospective food consumption have been demonstrated
[17], but changes in food intake could not be detected in a
small pilot study [28]. Regarding the effects of endogenous
GLP-1 on the CNS in humans, an association between post-
prandial increases in GLP-1 levels and the cerebral blood flow
in areas involved in feeding behaviour has been observed [29],
but our study is the first to investigate the effects of endoge-
nous GLP-1 in an interventional setting.
In the current study, we showed that blockade of endoge-
nous GLP-1 prevents the effects of meal intake on activation
in the insula in response to the viewing of food pictures. The
insula is known to be involved in the processing and evalua-
tion of food cues and in craving for food [30, 31]. Blocking the
actions of endogenous GLP-1 during the viewing of high-
energy pictures also affected activation in the OFC and cau-
date nucleus, which are known to be involved in the process of
reward evaluation [32]. In line with this finding, studies in
rodents suggest that GLP-1 may decrease the rewarding effect
of food by acting on central reward circuits [33, 34].
GLP-1 secreted from the intestine may access the brain
through areas with a permeable blood–brain barrier.
However, due to its short circulating half-life [35], it is likely
that only a small amount of gut-derived endogenous GLP-1
reaches the brain. Therefore, it has been suggested that central
effects of GLP-1 may also be mediated by indirect routes,
such as vagal afferents originating from the intestine where
GLP-1 levels are much higher [36]. In our study, we are not
able to distinguish the direct from indirect effects.
The effects of endogenous GLP-1 on the CNS in our study
might be explained by concomitant GLP-1 induced
glucometabolic or hormonal changes. Glucose and glucagon
have satiating effects that may be mediated by the CNS
[37, 38]. However, despite the higher glucose and glucagon
levels, we observed higher activation in the patients with dia-
betes compared with healthy lean individuals and higher CNS
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activation following exendin 9-39 administration compared
with placebo. Hence, differences in glucose and glucagon levels
cannot explain our findings and neither can insulin levels,
which did not differ between the groups nor between infusions.
Despite higher GLP-1 levels during exendin 9-39 administra-
tion, we observed that exendin 9-39 blocked GLP-1 effects.
In the healthy lean individuals, we were not able to detect a
significant effect of postprandial endogenous GLP-1 on acti-
vation in CNS reward and satiety circuits. Healthy lean indi-
viduals showed lower CNS activation during the presentation
of food pictures, possibly reducing the power to detect alter-
ations due to endogenous GLP-1. Similarly, in a previous
study, we were able to detect effects of pharmacological levels
of GLP-1RA in healthy (normoglycaemic) obese individuals
and obese patients with diabetes, whereas we [19] and others
[39] were not able to detect these effects in healthy lean indi-
viduals. In accordance, the effect of meal intake on CNS acti-
vation in healthy lean individuals in the present study was
much weaker than in patients with type 2 diabetes.
A limitation of this study is that we included only a group
of healthy (normoglycaemic) lean individuals and obese
patients with type 2 diabetes. We are, therefore, unable to
distinguish the effects of obesity from diabetes per se.
Although extrapolation of our findings in obese patients with
diabetes to healthy (normoglycaemic) obese individuals
awaits empirical confirmation, we believe that our findings
may extend to healthy obese individuals for several reasons.
First, in a previous study we showed that CNS activation in
response to viewing food pictures was similarly increased in
healthy obese individuals and in obese patients with type 2
diabetes [19]. Second, in this same study, we found that acute
GLP-1RA administration reduced CNS activation in response
to food pictures and reduced food intake in both healthy obese
individuals and in obese patients with diabetes [19]. Third,
several studies have shown that the effects of GLP-1RA treat-
ment on body weight and food intake are similar in healthy
obese individuals and in obese patients with diabetes
[8, 40–43]. Fourth, in accordance with the findings in our
study in obese patients with type 2 diabetes, others observed
that GLP-1 administration at physiological levels in healthy
Fig. 4 Effects of GLP-1 receptor blockade on CNS responses. Axial and
coronal slices showing average differences in activation in brain regions
where blockade of endogenous GLP-1 effects with exendin 9-39
prevented reducing effects of meal intake on activation to viewing food
pictures in (a) healthy lean individuals (right insula p=0.08) and
(b) patients with type 2 diabetes (bilateral insula p<0.05). The colour
scale reflects the T-value of functional activity. In the graphs, the BOLD
signal intensity (effect size [AU]) mean and SEM for healthy lean
individuals in (c) the right insula and in patients with diabetes in (d) the
right and (e) left insula. The effect of exendin 9-39 in patients with
diabetes in response to viewing high-energy food pictures is shown for
(f) the right OFC (p=0.04) and (g) left caudate nucleus (p=0.06) and left
insula (p=0.08). In the graphs, the signal intensity is plotted for (h) the
right OFC, (i) left caudate nucleus and (j) left insula. AU, arbitrary units;
ex9-39, exendin 9-39; high en., high-energy food pictures; plac, placebo
Fig. 5 Glucose and plasma hormone levels. Levels of (a) glucose,
(b) total GLP-1, (c) insulin and (d) glucagon during placebo (black)
and exendin 9-39 (white) infusion in healthy lean individuals (circles)
and obese patients with diabetes (squares). Data are mean ± SEM. Glu-
cose levels were higher in diabetic patients vs healthy lean individuals
(p<0.001). Exendin 9-39 administration had no effect on glucose levels
in healthy lean individuals (p=0.4), but increased glucose levels in
diabetic patients (p=0.001). GLP-1 levels were higher during exendin
9-39 vs placebo administration (healthy, lean p=0.04; diabetes p=
0.002). Insulin levels did not differ between groups nor between infusions
in both groups (p≥0.09). Glucagon levels were significantly higher in
diabetic vs healthy lean individuals, and in both groups during exendin
9-39 vs placebo administration (p≤0.004)
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obese men (without diabetes) resulted in decreased ratings of
hunger and prospective food consumption [44]. Finally, in the
present study, we demonstrated statistically significant effects
of endogenous GLP-1 on CNS activation not only in obese
patients with diabetes but also a trend in healthy lean individ-
uals, suggesting that these effects are not confined to obese
patients with diabetes.
Altered CNS activation after gastric distention has been
described in obese patients [45], which may underlie their
ability to consume large food volumes. However, in the cur-
rent study, scanning was performed during rest only. Gastric
distension may alter CNS baseline activity, but not necessarily
activation differences when viewing food vs non-food pic-
tures, as in the present study.
The reducing effect of GLP-1RA on gastric emptying is
well-known [46, 47]. It could be speculated that a difference
in the rate of gastric emptying between placebo and exendin
9-39 may have influenced our fMRI results. One study report-
ed that exendin 9-39 has a small but significant effect on
gastric emptying [48]. However, we performed the postpran-
dial fMRI 30 min after meal intake, while the reported effect
of exendin 9-39 on gastric emptying only started 45 min after
intake [48]. In addition, others did not report altered gastric
emptying by GLP-1 receptor blockade [49, 50].
In conclusion, our findings provide the first evidence that
endogenous GLP-1 mediates satiating effects in areas of the
CNS involved in satiety and reward in obese patients with
type 2 diabetes. These data provide further insight into the
central effects of peripheral signals, relaying information to
the CNS and affecting feeding behaviour. Increased under-
standing of these processes may contribute to the development
of new treatment strategies for obesity.
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